DK1171137T3 - Anvendelse af triacetyluridin til behandling af mitochondriale lidelser - Google Patents

Anvendelse af triacetyluridin til behandling af mitochondriale lidelser

Info

Publication number
DK1171137T3
DK1171137T3 DK00910321T DK00910321T DK1171137T3 DK 1171137 T3 DK1171137 T3 DK 1171137T3 DK 00910321 T DK00910321 T DK 00910321T DK 00910321 T DK00910321 T DK 00910321T DK 1171137 T3 DK1171137 T3 DK 1171137T3
Authority
DK
Denmark
Prior art keywords
mitochondrial disorders
treatment
triacetyluridine
methods
mitochondrial
Prior art date
Application number
DK00910321T
Other languages
English (en)
Inventor
Robert K Naviaux
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1171137T3 publication Critical patent/DK1171137T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK00910321T 1999-02-23 2000-02-23 Anvendelse af triacetyluridin til behandling af mitochondriale lidelser DK1171137T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12158899P 1999-02-23 1999-02-23
PCT/US2000/004663 WO2000050043A1 (en) 1999-02-23 2000-02-23 Methods of treatment of mitochondrial disorders

Publications (1)

Publication Number Publication Date
DK1171137T3 true DK1171137T3 (da) 2008-03-31

Family

ID=22397641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910321T DK1171137T3 (da) 1999-02-23 2000-02-23 Anvendelse af triacetyluridin til behandling af mitochondriale lidelser

Country Status (20)

Country Link
US (2) US7638501B1 (da)
EP (2) EP1808177B1 (da)
JP (1) JP4776780B2 (da)
KR (2) KR100758712B1 (da)
CN (2) CN1191835C (da)
AT (1) ATE381935T1 (da)
AU (1) AU776437B2 (da)
BR (1) BR0008447A (da)
CA (1) CA2362925C (da)
DE (1) DE60037578T2 (da)
DK (1) DK1171137T3 (da)
ES (1) ES2298130T3 (da)
HU (1) HU230191B1 (da)
IL (3) IL144964A0 (da)
MX (1) MXPA01008549A (da)
NZ (1) NZ513926A (da)
PT (1) PT1171137E (da)
RU (2) RU2394580C2 (da)
WO (1) WO2000050043A1 (da)
ZA (1) ZA200107727B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
ES2294850T3 (es) * 1998-07-31 2008-04-01 Massachusetts Institute Of Technology Tratamiento de la enfermedad de alzheimer mediante el aumento de los niveles de citidina in vivo.
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
EP1385831A2 (en) * 2001-04-11 2004-02-04 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
ES2269690T3 (es) * 2001-05-29 2007-04-01 The University Of British Columbia Aplicaciones farmacologicas de los ensayos de adn mitocondrial.
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
JP2006515891A (ja) * 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA021818B1 (ru) * 2005-09-15 2015-09-30 Эдисон Фармасьютикалз, Инк. Варианты хвостовой части редокс-активных лекарственных средств для лечения митохондриальных болезней и модуляция биомаркера энергетического обмена q10
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
EP2217075A4 (en) 2007-11-02 2012-01-25 Massachusetts Inst Technology METHODS OF CONTROLLING ADHESION TO URIDINE FOOD SUPPLEMENTATION AND THEIR USE
CN101612110B (zh) * 2008-06-23 2012-07-25 欣凯医药化工中间体（上海）有限公司 三乙酰尿苷缓释制剂及其制备方法
CA2736250C (en) 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2556832B1 (en) * 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease
WO2015106255A1 (en) 2014-01-13 2015-07-16 City Of Hope Multivalent oligonucleotide assemblies
EP3182980B1 (en) * 2014-08-19 2020-10-14 Wellstat Therapeutics Corporation Treatment of glycosylation deficiency diseases
FR3027804A1 (fr) * 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
BR112017022578A2 (pt) 2015-05-29 2018-07-17 The Board Of Trustees Of The Leland Stanford Junior University agentes nucleosídicos para a redução da atividade deletéria de genes que contém repetições estendidas de nucleotídeos
HUE062134T2 (hu) 2015-06-05 2023-09-28 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Mitokondriális betegségek kezelése
HUE046399T2 (hu) * 2015-06-17 2020-03-30 Univ Columbia Deoxinukleozid terápia kiegyensúlyozatlan nukleotid pool által okozott betegségek, ideértve a mitokondriális DNS depléciós szindrómát, kezelésére
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
KR101981843B1 (ko) 2016-09-13 2019-05-23 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 미토콘드리아 기능 개선용 조성물
JP2021519334A (ja) 2018-03-26 2021-08-10 クリア クリーク バイオ， インコーポレイテッド ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
JP2022546611A (ja) * 2019-09-05 2022-11-04 ミトレインボー セラピューティクス，インコーポレーテッド ミトコンドリアｄｎａ枯渇障害の処置
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
EP3970713A1 (en) 2020-09-16 2022-03-23 GV Squared S.r.l. Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells
CN113116900B (zh) * 2021-04-14 2022-07-08 兰州大学 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用
BE1030026B1 (fr) * 2022-06-14 2023-07-07 Dendrogenix Composés dérivés de stérols et composition pharmaceutique les comprenant pour leur utilisation dans la prévention, l’amélioration et/ou le traitement d’une pathologie liée à un déficit mitochondrial

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5356690A (en) * 1976-09-30 1978-05-23 Rikagaku Kenkyusho Purin compund sugar derivatives and their preparation
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
EP0355131B1 (en) 1987-10-28 1996-09-04 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
WO1989003837A1 (en) * 1987-10-28 1989-05-05 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US6060459A (en) 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7173017B1 (en) 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US6348451B1 (en) 1987-10-28 2002-02-19 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
ATE271614T1 (de) * 1992-05-28 2004-08-15 Ct For Molecular Biology And M Quinone-derivate zur verbesserung der zellulare bioenergie
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
CA2186636A1 (en) * 1994-03-30 1995-10-12 Corinna Herrnstadt Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects
JP3808121B2 (ja) * 1995-01-09 2006-08-09 日本メジフィジックス株式会社 低酸素症またはミトコンドリア機能障害診断剤
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais

Also Published As

Publication number Publication date
CN1341024A (zh) 2002-03-20
EP1171137B1 (en) 2007-12-26
PT1171137E (pt) 2008-03-17
CN1191835C (zh) 2005-03-09
EP1171137A1 (en) 2002-01-16
IL180528A (en) 2013-11-28
US20100098678A1 (en) 2010-04-22
CA2362925C (en) 2011-04-12
WO2000050043A1 (en) 2000-08-31
HU230191B1 (hu) 2015-09-28
AU3243400A (en) 2000-09-14
ZA200107727B (en) 2007-10-31
IL144964A (en) 2013-11-28
KR20070085864A (ko) 2007-08-27
EP1171137A4 (en) 2004-04-07
RU2005121711A (ru) 2007-01-20
KR20020031331A (ko) 2002-05-01
EP1808177A3 (en) 2010-07-28
RU2394580C2 (ru) 2010-07-20
CN1626107A (zh) 2005-06-15
EP1808177B1 (en) 2018-08-08
CA2362925A1 (en) 2000-08-31
DE60037578D1 (de) 2008-02-07
AU2004235661A1 (en) 2005-01-27
IL180528A0 (en) 2007-06-03
RU2268732C2 (ru) 2006-01-27
ES2298130T3 (es) 2008-05-16
JP4776780B2 (ja) 2011-09-21
AU776437B2 (en) 2004-09-09
KR100758712B1 (ko) 2007-09-14
DE60037578T2 (de) 2009-01-08
US7638501B1 (en) 2009-12-29
KR100879559B1 (ko) 2009-01-22
US8748408B2 (en) 2014-06-10
HUP0400914A2 (hu) 2004-08-30
NZ513926A (en) 2001-09-28
BR0008447A (pt) 2002-01-15
EP1808177A2 (en) 2007-07-18
IL144964A0 (en) 2002-06-30
MXPA01008549A (es) 2003-06-06
ATE381935T1 (de) 2008-01-15
CN100379426C (zh) 2008-04-09
JP2002537340A (ja) 2002-11-05
HUP0400914A3 (en) 2007-05-29
RU2001125913A (ru) 2005-02-20

Similar Documents

Publication Publication Date Title
DK1171137T3 (da) Anvendelse af triacetyluridin til behandling af mitochondriale lidelser
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO20071095L (no) Hittil ukjente tiofenderivater
ATE504557T1 (de) Aspirin-ausgelöste lipidmediatoren
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
NO20035524D0 (no) 4'-substituerte nukleosider
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ES2318119T3 (es) Procedimiento y composiciones para alterar el perfil del efecto edulcorante de la sucralosa.
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
BRPI0407512A (pt) derivados de indolilmaleimida
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
ATE511512T1 (de) Olanzapinpamoat-dihydrat
NO20065791L (no) Asyklovir-formuleringer
DK1220852T3 (da) Substituerede diazepaner
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
NO20060420L (no) 2-aminobenzoylderivater